Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 12/20 | 0.65 |
| ▸ | HTR2A | P28223 | 3/20 | 0.65 |
| ▸ | HTR1A | P08908 | 2/20 | 0.65 |
| ▸ | DRD2 | P14416 | 2/20 | 0.65 |
| ▸ | HTR7 | P34969 | 2/20 | 0.65 |
| ▸ | MC5R | P33032 | 2/20 | 0.59 |
| ▸ | MC3R | P41968 | 2/20 | 0.59 |
| ▸ | MC1R | Q01726 | 2/20 | 0.59 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.54 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18409331 | 0.87 | PDE10A (0.54) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL18409642 | 0.85 | NR4A2 (0.53) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL18409568 | 0.83 | GPR84 (0.57) | NR4A2 | |
| SCHEMBL18409691 | 0.81 | SMN1; SMN2 (0.54) | HTR2ADRD2NR4A2 | |
| SCHEMBL20414447 | 0.78 | NR4A2 (0.53) | HTR2ADRD2NR4A2 | |
| SCHEMBL18409692 | 0.78 | HTR6 (0.53) | HTR6HTR2AHTR1ADRD2HTR7 | |
| Hydrochloric Acid SCHEMBL11711794 | 0.78 | NR4A2 (0.61) | HTR2ADRD2NR4A2 | |
| SCHEMBL22692981 | 0.78 | NR4A2 (0.46) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL18409348 | 0.77 | HTR6 (0.61) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL18409639 | 0.76 | GPR84 (0.52) | HTR1ANR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844051-B2 | Substituted oxazoles for the treatment of cancer | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY | 2020-11-24 | — | — | US | disclosed |
| US-20200339554-A1 | COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2020-10-29 | — | — | US | disclosed |
| US-20180208586-A1 | COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2018-07-26 | — | — | US | disclosed |
| WO-2017011920-A1 | COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2017-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208586-A1 | COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS | VHL, TP53, CD44 | HTR6 4055/4885HTR2A 4576/4885HTR1A 4682/4885 |
| US-10844051-B2 | Substituted oxazoles for the treatment of cancer | OXA1L, PDCD1, MCL1 | HTR6 4248/4885HTR2A 4582/4885HTR1A 4617/4885 |
| US-20200339554-A1 | COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS | KRAS, NRAS, VHL | HTR6 4759/4885HTR2A 4856/4885HTR1A 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.